ABIVAX Shares Surge 15% in a Week, Annual Results on the Horizon
The stock of French biotech ABIVAX shows a strong increase this afternoon, trading at 109 euros, up 1.68% from the previous close of 107.20 euros. This movement follows a significant crossing of the 50-day moving average during the last session, a signal that adds to an unusually marked daily variation exceeding the 5% alert threshold. Over the past seven days, the stock has shown a nearly 15% increase, in a context of a rising Parisian market, with the CAC 40 gaining 0.88% in session.
Crossing the 50-Day Moving Average
ABIVAX reconnected with its 50-day moving average (MM50) during the session on Monday, March 16, with the closing price at 107.20 euros above this threshold set at 102.18 euros. This crossing is particularly significant given the recent history: from the beginning of March to March 13, the stock consistently traded below this average, fluctuating between 94 and 101.20 euros, indicating a prolonged consolidation phase. Since then, the dynamic has reversed. Currently at 109 euros, the stock is approaching the resistance identified at 112.40 euros, last reached on February 20. The MM200, which stands at 73.77 euros, remains well below the current price, reflecting the progress made over the year — the annual performance reaching +1,896%. The RSI at 48 indicates a neutral situation, without excess in either direction.
Exceeding the Normal Variation Threshold
Beyond the graphical aspect, the recorded variation exceeds the statistically qualified abnormal threshold, set at 5%. When the signal was detected, the daily increase was approximately 5.93%, before a slight stabilization during today's session at +1.68%, bringing the price to 109 euros. This resurgence of activity occurs less than a week before the publication of the annual results for 2025, scheduled for March 23. Investors will soon have a first complete overview of the past fiscal year, before the quarterly and semi-annual publications scheduled until December 2026. Over three months, the stock's progression remains modest at +1.3%, which puts the recent movement into perspective from a medium-term viewpoint. The monthly volatility, at 14.99%, reflects the usual sensitivity of this type of stock to information catalysts.
